The effectiveness of repetitive transcranial magnetic stimulation in the treatment of fibromyalgia

• Conditions: Fibromyalgia; Chronic Pain; Mental Health; Musculoskeletal - Other muscular and skeletal disorders; Mental Health - Depression

• Registration Number: ACTRN12613000561785
• Lead Sponsor: Dr Bernadette Fitzgibbon

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-05-17
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Stopped early
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Participants will be included if they:
* are aged between 18-65 years,
* meet American College of Rheumatology Fibromyalgia Scale (2010) diagnostic criteria for Fibromyalgia
* have experienced symptoms for > 6 months
* have had no change in medication in the four weeks prior to trial initiation.

Exclusion Criteria

* History of epilepsy or seizure disorder
* History of serious head injury
* Metal in the head (outside of the mouth)
* Medical implants in the body
* History or diagnosis of neurological/psychiatric illness
* Specific pathological entities, such as infection, neoplasm, metastasis, osteoporosis, rheumatoid arthritis or fracture
* Additional co-existing musculoskeletal conditions
* Pregnant
* Professional driver or machine operator.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in severity and impact of pain as measured by the Short-form McGill Pain Questionnaire and the Brief Pain Inventory.[At the end of treatment course (week 4).];Change in quality of life as measured by the Short-form 36 Health Survey and the Fibromyalgia impact questionnaire.[End of treatment course (week 4).]

Secondary Outcome Measures

Name	Time	Method
Change in severity of depressive symptoms as shown by score of the Beck Depression Inventory (BDI).[End of treatment course (week 4).];Change in Multi-dimensional Fatigue Inventory score[Baseline compared to end of treamtent at 4 weeks and 1 month follow up];Change in Pain Catastrophisation Scale[Baseline compared to end of treatment at 4 weeks and 1 month follow up];Change in Beck Anxiety Inventory and State-Trait Anxiety Inventory scores[Baseline compared to end of treatment (4 weeks) compared to follow-up (1 month post treatment).]